The Conversation (0)
CorMedix announced an increase to its public offering, bringing the gross proceeds up to $12.1 million approximately.
CorMedix (NYSEMKT:CRMD) announced an increase to its public offering, bringing the gross proceeds up to $12.1 million approximately.
As quoted in the press release:
Due to demand, the underwriter has agreed to increase the size of the offering by 21% and purchase 16,190,697 shares of common stock of the Company, together with Tranche 1 Warrants to purchase 12,143,022 shares of common stock of the Company and Tranche 2 Warrants to purchase 12,143,022 shares of common stock of the Company, at a price to the public of $0.75 per share and accompanying warrants.
H.C. Wainwright & Co. is acting as the sole book-running manager for this offering.
The aggregate gross proceeds to the Company are approximately $12.1 million, before deducting underwriting discounts and commissions and estimated offering expenses. All shares of common stock issued in connection with this offering will be listed on the NYSE MKT and will be freely tradable on such exchange.
Click here to read the full press release.
Source: www.accesswire.com
